GR1603

GR1603 · Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GR1603, covering 2024-09-25 to 2024-09-25. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE [Phase 1, Phase 2]